WCT has now made five acquisitions in the past year as it seeks to establish itself at the forefront of the contract research sector. Through these acquisitions WCT has gained a presence in more than 30 countries, with the latest take over extending its reach in Eastern, Central and Southern Europe. Dr Neal Cutler, founder of WCT, said: "The acquisitions we have completed to date significantly enhance our contract research organization capabilities and our ability to manage large, global trials, within our primary therapeutic areas of focus. That in turn positions us well for future growth. "We have effectively expanded our operations and significantly enhanced our ability to meet the global needs of pharma and biotech companies. Our presence in Eastern Europe and Russia, two of the most attractive growth regions for clinical trials, helps transform our business into a truly global contract research organization." The purchase of Serbia based MediQuest fits in with the selective purchases made over the past 12 months by WCT. Financial details of this latest acquisition have not been disclosed. WCT has stated these acquisitions are intended to extend the geographical reach of the company and provide it with complementary skills and facilities. Over the past 12 months WCT has bought Russian companies Evidence Clinical and Pharmaceutical Research, US-based Clinical Studies Management Group and bioanalytical chemistry specialist CEDRA, and Nottingham Clinical Research, which has its headquarters in the UK. These acquisitions highlight the ambition of the US-based contract research organisation (CRO), which primarily focuses on research into central nervous system (CNS) and cardiovascular diseases. In addition to its primary focus on CNS and cardiovascular diseases the company also has experience in treatments for chronic inflammatory disease, metabolism, endocrinology and oncology. Within these areas of expertise WCT supplies Phase I-IV drug development services to pharmaceutical and biotechnology companies. The company claims to have increased the quality, safety and speed of drug development by pioneering "revolutionary and innovative" techniques, such as the Bridging and Dynabridge studies.